Mevalonate Cascade and Neurodevelopmental and Neurodegenerative Diseases: Future Targets for Therapeutic Application

Author(s): Xiaodan Jiao, Niloufar Ashtari, Maryam Rahimi-Balaei, Qi Min Chen, Ilnaz Badbezanchi, Shahla Shojaei, Adel Marzban, Nima Mirzaei, Seunghyuk Chung, Teng Guan, Jiasi Li, Jerry Vriend, Shahram Ejtemaei Mehr, Jiming Kong, Hassan Marzban*.

Journal Name: Current Molecular Pharmacology

Volume 10 , Issue 2 , 2017

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

The mevalonate cascade is a key metabolic pathway that regulates a variety of cellular functions and is thereby implicated in the pathophysiology of most brain diseases, including neurodevelopmental and neurodegenerative disorders. Emerging lines of evidence suggest that statins and Rho GTPase inhibitors are efficacious and have advantageous properties in treatment of different pathologic conditions that are relevant to the central nervous system. Beyond the original role of statins in lowering cholesterol synthesis, they have anti-inflammatory, antioxidant and modulatory effects on signaling pathways. Additionally, Rho GTPase inhibitors and statins share the mevalonate pathway as a common target of their therapeutic actions. In this review, we discuss potential mechanisms through which these drugs, via their role in the mevalonate pathway, exert their neuroprotective effects in neurodegenerative and neurodevelopmental disorders.

Keywords: Cholesterol, neurodegeneration, neurodevelopment, Rho GTPase, statins.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 10
ISSUE: 2
Year: 2017
Page: [115 - 140]
Pages: 26
DOI: 10.2174/1874467209666160112125446
Price: $58

Article Metrics

PDF: 27
HTML: 3